



Emerging Challenges In Primary Care: *2012*

Activity Evaluation Summary

CME Activity: Emerging Challenges in Primary Care: 2012
Saturday, October 20, 2012
DoubleTree by Hilton Nashville Downtown
Nashville, TN

Course Director: Gregg Sherman, MD

**Date of Evaluation
Summary:** December 4, 2012



300 NW 70th Avenue, Suite 102 • Plantation, Florida 33317
(954) 723-0057 Phone • (954) 723-0353 Fax
email: info@naceonline.com

In October 2012, the National Association for Continuing Education (NACE) sponsored a CME program, *Emerging Challenges in Primary Care: 2012*, in Nashville, TN.

This educational activity was designed to provide primary care physicians, nurse practitioners, physician assistants and other primary care providers the opportunity to learn about Diabetes, Atrial Fibrillation, Inflammatory Bowel Disease, Osteoporosis, Pulmonary Arterial Hypertension, Alpha-1 Antitrypsin Disorder, and Chronic Low Back Pain.

In planning this CME activity, the NACE performed a needs assessment. A literature search was conducted, national guidelines were reviewed, survey data was analyzed, and experts in each therapeutic area were consulted to determine gaps in practitioner knowledge, competence or performance.

Two hundred forty four healthcare practitioners registered to attend *Emerging Challenges in Primary Care: 2012* in Nashville, TN. One hundred thirty one healthcare practitioners actually attended this conference. Each attendee was asked to complete and return an activity evaluation form prior to the end of the conference. One hundred thirty completed forms were received. The data collected is displayed in this report.


CME ACCREDITATION

The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Association for Continuing Education designates this live activity for a maximum of 7 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


What is your professional degree?

| Label | Frequency | Percent | Valid Percent |
|-------------|-----------|---------|---------------|
| MD | 81 | 62.31 | 62.31 |
| DO | 6 | 4.62 | 4.62 |
| NP | 32 | 24.62 | 24.62 |
| PA | 8 | 6.15 | 6.15 |
| RN | 1 | 0.77 | 0.77 |
| Other | 2 | 1.54 | 1.54 |
| Total Valid | 130 | 100.00 | 100.00 |




What is your specialty?

| Label | Frequency | Percent | Valid Percent |
|------------------|-----------|---------|---------------|
| Primary Care | 107 | 82.31 | 83.59 |
| Endocrinology | 1 | 0.77 | 0.78 |
| Rheumatology | 0 | 0.00 | 0.00 |
| Pulmonology | 0 | 0.00 | 0.00 |
| Cardiology | 1 | 0.77 | 0.78 |
| Gastroenterology | 0 | 0.00 | 0.00 |
| OB/GYN | 5 | 3.85 | 3.91 |
| Other | 14 | 10.77 | 10.94 |
| Total Valid | 128 | 98.46 | 100.00 |
| Total Missing | 2 | 1.54 | |
| Total | 130 | 100.00 | |




Upon completion of this activity, I can now - Address the importance of early diagnosis for enhancing outcomes in type 2 diabetes; identify evidence-based strategies for type 2 diabetes management; discuss the role of newer therapies in the pathophysiology and management of type 2 diabetes; and discuss the role of the chronic care model in optimizing diabetes care:

| Label | Frequency | Percent | Valid Percent |
|---------------|-----------|---------|---------------|
| Yes | 112 | 86.15 | 88.89 |
| Somewhat | 14 | 10.77 | 11.11 |
| Not at all | 0 | 0.00 | 0.00 |
| Total Valid | 126 | 96.92 | 100.00 |
| Total Missing | 4 | 3.08 | |
| Total | 130 | 100.00 | |




Upon completion of this activity, I can now - Use the CHADS2 score to assess stroke risk in patients with atrial fibrillation (AF); describe the benefits versus risks of antithrombotic therapy for stroke risk reduction in AF patients; identify appropriate therapeutic interventions for AF patients depending on the level of stroke risk; optimize the long-term management of AF patients receiving antithrombotic therapy:

| Label | Frequency | Percent | Valid Percent |
|---------------|-----------|---------|---------------|
| Yes | 121 | 93.08 | 94.53 |
| Somewhat | 7 | 5.38 | 5.47 |
| Not at all | 0 | 0.00 | 0.00 |
| Total Valid | 128 | 98.46 | 100.00 |
| Total Missing | 2 | 1.54 | |
| Total | 130 | 100.00 | |




Upon completion of this activity, I can now - Discuss the pathophysiology of low back pain (LBP); recognize Waddell signs and how they can predict symptom magnification; recognize the limitations of some commonly prescribed therapies for back pain; demonstrate increased awareness of evolving pharmacotherapies and their role in low back pain:

| Label | Frequency | Percent | Valid Percent |
|---------------|-----------|---------|---------------|
| Yes | 119 | 91.54 | 92.97 |
| Somewhat | 9 | 6.92 | 7.03 |
| Not at all | 0 | 0.00 | 0.00 |
| Total Valid | 128 | 98.46 | 100.00 |
| Total Missing | 2 | 1.54 | |
| Total | 130 | 100.00 | |




Upon completion of this activity, I can now - Identify the conditions referred to as inflammatory bowel disease (IBD), and discuss their clinical presentations; implement appropriate pharmacologic and non-pharmacologic therapeutic strategies for managing IBD in accordance with evidence-based guidelines; tailor the available medications to the various presentations of IBD with attention to the induction and the maintenance of remission; use currently available laboratory tests to maximize benefit while minimizing toxicity; employ approaches for effectively communicating the risks and benefits of IBD treatment options and facilitating adherence:

| Label | Frequency | Percent | Valid Percent |
|---------------|-----------|---------|---------------|
| Yes | 102 | 78.46 | 80.31 |
| Somewhat | 25 | 19.23 | 19.69 |
| Not at all | 0 | 0.00 | 0.00 |
| Total Valid | 127 | 97.69 | 100.00 |
| Total Missing | 3 | 2.31 | |
| Total | 130 | 100.00 | |




Upon completion of this activity, I can now - Discuss screening strategies for osteoporosis in postmenopausal women; identify candidates for pharmacologic treatment of postmenopausal osteoporosis; evaluate and compare available therapies for osteoporosis; and discuss barriers to adherence and effectiveness of osteoporosis therapy:

| Label | Frequency | Percent | Valid Percent |
|---------------|-----------|---------|---------------|
| Yes | 112 | 86.15 | 91.80 |
| Somewhat | 8 | 6.15 | 6.56 |
| Not at all | 2 | 1.54 | 1.64 |
| Total Valid | 122 | 93.85 | 100.00 |
| Total Missing | 8 | 6.15 | |
| Total | 130 | 100.00 | |




Upon completion of this activity, I can now - Address the pathophysiology of PAH; discuss when and how to screen patients for PAH; identify current therapies in the management of PAH; and discuss how to appropriately monitor patients receiving treatment for PAH:

| Label | Frequency | Percent | Valid Percent |
|---------------|-----------|---------|---------------|
| Yes | 73 | 56.15 | 64.60 |
| Somewhat | 32 | 24.62 | 28.32 |
| Not at all | 8 | 6.15 | 7.08 |
| Total Valid | 113 | 86.92 | 100.00 |
| Total Missing | 17 | 13.08 | |
| Total | 130 | 100.00 | |




Upon completion of this activity, I can now - Describe the pathophysiology and impact of AAT deficiency; Define approaches for the early identification of patients with AAT deficiency; Discuss strategies to improve testing in primary care settings; Discuss management of patients with AAT:

| Label | Frequency | Percent | Valid Percent |
|---------------|-----------|---------|---------------|
| Yes | 84 | 64.62 | 81.55 |
| Somewhat | 17 | 13.08 | 16.50 |
| Not at all | 2 | 1.54 | 1.94 |
| Total Valid | 103 | 79.23 | 100.00 |
| Total Missing | 27 | 20.77 | |
| Total | 130 | 100.00 | |




Overall, I would rate this activity as:

| Label | Frequency | Percent | Valid Percent |
|---------------|-----------|---------|---------------|
| Excellent | 76 | 58.46 | 59.84 |
| Very Good | 47 | 36.15 | 37.01 |
| Good | 4 | 3.08 | 3.15 |
| Fair | 0 | 0.00 | 0.00 |
| Poor | 0 | 0.00 | 0.00 |
| Total Valid | 127 | 97.69 | 100.00 |
| Total Missing | 3 | 2.31 | |
| Total | 130 | 100.00 | |




Overall, this activity was effective in enhancing my confidence in caring for patients with the condition(s) presented?

| Label | Frequency | Percent | Valid Percent |
|-------------------|-----------|---------|---------------|
| Strongly Agree | 73 | 56.15 | 57.48 |
| Agree | 53 | 40.77 | 41.73 |
| Neutral | 1 | 0.77 | 0.79 |
| Disagree | 0 | 0.00 | 0.00 |
| Strongly Disagree | 0 | 0.00 | 0.00 |
| Total Valid | 127 | 97.69 | 100.00 |
| Total Missing | 3 | 2.31 | |
| Total | 130 | 100.00 | |




Overall, this activity was effective in improving my knowledge in the content areas presented:

| Label | Frequency | Percent | Valid Percent |
|-------------------|-----------|---------|---------------|
| Strongly Agree | 80 | 61.54 | 62.50 |
| Agree | 47 | 36.15 | 36.72 |
| Neutral | 1 | 0.77 | 0.78 |
| Disagree | 0 | 0.00 | 0.00 |
| Strongly Disagree | 0 | 0.00 | 0.00 |
| Total Valid | 128 | 98.46 | 100.00 |
| Total Missing | 2 | 1.54 | |
| Total | 130 | 100.00 | |




As a result of this activity, I have learned new strategies for patient care:

| Label | Frequency | Percent | Valid Percent |
|-------------------|-----------|---------|---------------|
| Strongly Agree | 80 | 61.54 | 62.50 |
| Agree | 45 | 34.62 | 35.16 |
| Neutral | 3 | 2.31 | 2.34 |
| Disagree | 0 | 0.00 | 0.00 |
| Strongly Disagree | 0 | 0.00 | 0.00 |
| Total Valid | 128 | 98.46 | 100.00 |
| Total Missing | 2 | 1.54 | |
| Total | 130 | 100.00 | |




How likely are you to implement these new strategies in your practice?

| Label | Frequency | Percent | Valid Percent |
|-----------------|-----------|---------|---------------|
| Very likely | 99 | 76.15 | 79.84 |
| Somewhat likely | 18 | 13.85 | 14.52 |
| Unlikely | 0 | 0.00 | 0.00 |
| Not applicable | 7 | 5.38 | 5.65 |
| Total Valid | 124 | 95.38 | 100.00 |
| Total Missing | 6 | 4.62 | |
| Total | 130 | 100.00 | |




When do you intend to implement these new strategies into your practice?

| Label | Frequency | Percent | Valid Percent |
|----------------|-----------|---------|---------------|
| Within 1 month | 90 | 69.23 | 73.77 |
| 1-3 months | 20 | 15.38 | 16.39 |
| 4-6 months | 2 | 1.54 | 1.64 |
| Not applicable | 10 | 7.69 | 8.20 |
| Total Valid | 122 | 93.85 | 100.00 |
| Total Missing | 8 | 6.15 | |
| Total | 130 | 100.00 | |




In terms of delivery of the presentation, please rate the effectiveness of the speaker: Mark Stolar, MD (Diabetes):

| Label | Frequency | Percent | Valid Percent |
|----------------|-----------|---------|---------------|
| Excellent | 89 | 68.46 | 70.63 |
| Very Good | 28 | 21.54 | 22.22 |
| Good | 8 | 6.15 | 6.35 |
| Fair | 1 | 0.77 | 0.79 |
| Unsatisfactory | 0 | 0.00 | 0.00 |
| Total Valid | 126 | 96.92 | 100.00 |
| Total Missing | 4 | 3.08 | |
| Total | 130 | 100.00 | |




In terms of delivery of the presentation, please rate the effectiveness of the speaker: Louis Kuritzky, MD (A Fib):

| Label | Frequency | Percent | Valid Percent |
|----------------|-----------|---------|---------------|
| Excellent | 112 | 86.15 | 87.50 |
| Very Good | 15 | 11.54 | 11.72 |
| Good | 1 | 0.77 | 0.78 |
| Fair | 0 | 0.00 | 0.00 |
| Unsatisfactory | 0 | 0.00 | 0.00 |
| Total Valid | 128 | 98.46 | 100.00 |
| Total Missing | 2 | 1.54 | |
| Total | 130 | 100.00 | |




In terms of delivery of the presentation, please rate the effectiveness of the speaker: Louis Kuritzky, MD (CLBP):

| Label | Frequency | Percent | Valid Percent |
|----------------|-----------|---------|---------------|
| Excellent | 110 | 84.62 | 86.61 |
| Very Good | 17 | 13.08 | 13.39 |
| Good | 0 | 0.00 | 0.00 |
| Fair | 0 | 0.00 | 0.00 |
| Unsatisfactory | 0 | 0.00 | 0.00 |
| Total Valid | 127 | 97.69 | 100.00 |
| Total Missing | 3 | 2.31 | |
| Total | 130 | 100.00 | |




In terms of delivery of the presentation, please rate the effectiveness of the speaker: Gerald W. Dryden, MD (IBD):

| Label | Frequency | Percent | Valid Percent |
|----------------|-----------|---------|---------------|
| Excellent | 76 | 58.46 | 61.79 |
| Very Good | 35 | 26.92 | 28.46 |
| Good | 10 | 7.69 | 8.13 |
| Fair | 1 | 0.77 | 0.81 |
| Unsatisfactory | 1 | 0.77 | 0.81 |
| Total Valid | 123 | 94.62 | 100.00 |
| Total Missing | 7 | 5.38 | |
| Total | 130 | 100.00 | |




In terms of delivery of the presentation, please rate the effectiveness of the speaker: Marjorie Luckey, MD (Osteo):

| Label | Frequency | Percent | Valid Percent |
|----------------|-----------|---------|---------------|
| Excellent | 85 | 65.38 | 72.03 |
| Very Good | 29 | 22.31 | 24.58 |
| Good | 1 | 0.77 | 0.85 |
| Fair | 3 | 2.31 | 2.54 |
| Unsatisfactory | 0 | 0.00 | 0.00 |
| Total Valid | 118 | 90.77 | 100.00 |
| Total Missing | 12 | 9.23 | |
| Total | 130 | 100.00 | |




In terms of delivery of the presentation, please rate the effectiveness of the speaker: Franck Rahaghi, MD (PAH):

| Label | Frequency | Percent | Valid Percent |
|----------------|-----------|---------|---------------|
| Excellent | 54 | 41.54 | 53.47 |
| Very Good | 33 | 25.38 | 32.67 |
| Good | 8 | 6.15 | 7.92 |
| Fair | 5 | 3.85 | 4.95 |
| Unsatisfactory | 1 | 0.77 | 0.99 |
| Total Valid | 101 | 77.69 | 100.00 |
| Total Missing | 29 | 22.31 | |
| Total | 130 | 100.00 | |




In terms of delivery of the presentation, please rate the effectiveness of the speaker: Franck Rahaghi, MD (AAT):

| Label | Frequency | Percent | Valid Percent |
|----------------|-----------|---------|---------------|
| Excellent | 54 | 41.54 | 60.67 |
| Very Good | 27 | 20.77 | 30.34 |
| Good | 3 | 2.31 | 3.37 |
| Fair | 4 | 3.08 | 4.49 |
| Unsatisfactory | 1 | 0.77 | 1.12 |
| Total Valid | 89 | 68.46 | 100.00 |
| Total Missing | 41 | 31.54 | |
| Total | 130 | 100.00 | |




To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Mark Stolar, MD (Diabetes):

| Label | Frequency | Percent | Valid Percent |
|----------------|-----------|---------|---------------|
| Excellent | 102 | 78.46 | 82.26 |
| Very Good | 21 | 16.15 | 16.94 |
| Good | 0 | 0.00 | 0.00 |
| Fair | 1 | 0.77 | 0.81 |
| Unsatisfactory | 0 | 0.00 | 0.00 |
| Total Valid | 124 | 95.38 | 100.00 |
| Total Missing | 6 | 4.62 | |
| Total | 130 | 100.00 | |




To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Louis Kuritzky, MD (A Fib):

| Label | Frequency | Percent | Valid Percent |
|----------------|-----------|---------|---------------|
| Excellent | 109 | 83.85 | 87.20 |
| Very Good | 15 | 11.54 | 12.00 |
| Good | 0 | 0.00 | 0.00 |
| Fair | 1 | 0.77 | 0.80 |
| Unsatisfactory | 0 | 0.00 | 0.00 |
| Total Valid | 125 | 96.15 | 100.00 |
| Total Missing | 5 | 3.85 | |
| Total | 130 | 100.00 | |




To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Louis Kuritzky, MD (CLBP):

| Label | Frequency | Percent | Valid Percent |
|----------------|-----------|---------|---------------|
| Excellent | 110 | 84.62 | 88.00 |
| Very Good | 14 | 10.77 | 11.20 |
| Good | 0 | 0.00 | 0.00 |
| Fair | 1 | 0.77 | 0.80 |
| Unsatisfactory | 0 | 0.00 | 0.00 |
| Total Valid | 125 | 96.15 | 100.00 |
| Total Missing | 5 | 3.85 | |
| Total | 130 | 100.00 | |




To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Gerald W. Dryden, MD (IBD):

| Label | Frequency | Percent | Valid Percent |
|----------------|-----------|---------|---------------|
| Excellent | 101 | 77.69 | 82.11 |
| Very Good | 22 | 16.92 | 17.89 |
| Good | 0 | 0.00 | 0.00 |
| Fair | 0 | 0.00 | 0.00 |
| Unsatisfactory | 0 | 0.00 | 0.00 |
| Total Valid | 123 | 94.62 | 100.00 |
| Total Missing | 7 | 5.38 | |
| Total | 130 | 100.00 | |




To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Marjorie Luckey, MD (Osteo):

| Label | Frequency | Percent | Valid Percent |
|----------------|-----------|---------|---------------|
| Excellent | 99 | 76.15 | 83.19 |
| Very Good | 16 | 12.31 | 13.45 |
| Good | 3 | 2.31 | 2.52 |
| Fair | 1 | 0.77 | 0.84 |
| Unsatisfactory | 0 | 0.00 | 0.00 |
| Total Valid | 119 | 91.54 | 100.00 |
| Total Missing | 11 | 8.46 | |
| Total | 130 | 100.00 | |




To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Franck Rahaghi, MD (PAH):

| Label | Frequency | Percent | Valid Percent |
|----------------|-----------|---------|---------------|
| Excellent | 92 | 70.77 | 83.64 |
| Very Good | 15 | 11.54 | 13.64 |
| Good | 2 | 1.54 | 1.82 |
| Fair | 0 | 0.00 | 0.00 |
| Unsatisfactory | 1 | 0.77 | 0.91 |
| Total Valid | 110 | 84.62 | 100.00 |
| Total Missing | 20 | 15.38 | |
| Total | 130 | 100.00 | |




To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Franck Rahaghi, MD (AAT):

| Label | Frequency | Percent | Valid Percent |
|----------------|-----------|---------|---------------|
| Excellent | 86 | 66.15 | 84.31 |
| Very Good | 15 | 11.54 | 14.71 |
| Good | 0 | 0.00 | 0.00 |
| Fair | 0 | 0.00 | 0.00 |
| Unsatisfactory | 1 | 0.77 | 0.98 |
| Total Valid | 102 | 78.46 | 100.00 |
| Total Missing | 28 | 21.54 | |
| Total | 130 | 100.00 | |




Which statement(s) best reflects your reasons for participating in this activity:

| Label | Frequency | Percent | Valid Percent |
|-------------------------|-----------|---------|---------------|
| Topics covered | 95 | 73.08 | 74.22 |
| Location/ease of access | 96 | 73.85 | 75.00 |
| Faculty | 26 | 20.00 | 20.31 |
| Earn CME credits | 105 | 80.77 | 82.03 |
| Total Valid | 128 | 98.46 | 100.00 |
| Total Missing | 2 | 1.54 | |
| Total | 130 | 100.00 | |



Future CME activities concerning this subject matter are necessary:

| Label | Frequency | Percent | Valid Percent |
|-------------------|-----------|---------|---------------|
| Strongly agree | 64 | 49.23 | 50.39 |
| Agree | 54 | 41.54 | 42.52 |
| Neutral | 8 | 6.15 | 6.30 |
| Disagree | 1 | 0.77 | 0.79 |
| Strongly Disagree | 0 | 0.00 | 0.00 |
| Total Valid | 127 | 97.69 | 100.00 |
| Total Missing | 3 | 2.31 | |
| Total | 130 | 100.00 | |



What is your professional degree?

| Comment |
|---------|
| PhD |
| DNP |
| PhD |

What is your specialty?

| Comment |
|-----------------------|
| Emergency Medicine |
| Allergy |
| Dermatology |
| ER |
| Urgent Care |
| Heart Failure |
| Acute Care |
| Hospice |
| Psychiatry |
| Occupational Medicine |
| Pediatrics |
| Urgent Care |
| Family Practice |
| Preventive Medicine |
| Medical Oncology |
| Epidemiology |
| Wound Care |

As a result of this activity, I have learned new strategies for patient care. List these strategies:

| Comment |
|--|
| CHADS score |
| Decrease use of radiology testing on LBP |
| Increase osteoporosis screening |
| Will use GLP-1 and CHADS more |
| Better screening of patients with IBD/IBS |
| New developments in primary care guidelines |
| Treatment of diabetes |
| Treat young diabetics early and aggressive |
| Will use evidence based studies to inform patients |
| LBP management and use CHADS more |
| Narcotics for LBP |
| Change in diabetes management |
| LBP management |

| Comment |
|---|
| Use CHADS scale |
| Different treatments |
| Screen more for HTN |
| Proper assessment and avoiding longterm narcotic use |
| Use FRAX for osteoporosis |
| Advocating patients |
| Treatment of A Fib and pharmacology strategies for osteoporosis |
| New A Fib recommendations |
| Use CHADS more often |
| Testing treatment therapy |
| Diabetes treatment earlier |
| Improved A Fib and LBP treatment |
| LBP treatment |
| Use CHADS more often |
| Type 2 Diabetes treatment and better osteoporosis treatment |
| Test for AAT |
| Improved utilization of CHADS |
| Management of LBP and will use CHADS |
| I will use CHADS score and FRAX |
| Diabetes management |
| Screening for osteoporosis |
| IBD/IBS management |
| Newer medications |
| CHADS and LBP treatment |
| Back pain and diabetes treatment |
| Change my diabetes management |
| Use CHADS and FRX criteria for treatment decisions |
| Better lower back pain control |
| Do more AAT screening |
| Better use of CHADS |
| Will use more meds for osteoporosis |
| New treatment for LBP |
| IBD diagnosis |
| More aggressive treating young diabetic patients |
| Refer to endocrinology sooner |
| Use of CHADS. Use of Waddells signs with LBP |
| BDT for all >65 years |
| Use of CHADS score |
| ASA and usage |
| Do more AAT screening |
| FRAX |

What topics would you like to see offered as CME activities in the

future?

| |
|---|
| Comment |
| Inpatient medicine topics |
| Hormone replacement and CKD management |
| Emergency topics |
| Womens health |
| CKD and PVD |
| Current trends in pediatrics |
| Women's Health |
| Hyperthyroidism |
| HTN |
| Hepatitis C |
| More on LBP |
| Atrial Fib |
| Use of EMR in Primary Care |
| Update on HIV |
| GYN issues and pelvic pain |
| Oncology |
| Men's health |
| Dermatology |
| Urgent care and occupational medicine |
| CKD and hepatitis |
| Breast cancer update |
| Renal disease |
| Stroke and HTN |
| Obesity |
| Sleep apnea and GYN updates |
| Lipid agents and use |
| Infectious diseases |
| Pain management |
| Chronic renal failure and liver cirrhosis |
| Depression |
| Breast cancer and vitamins |
| Neurology |
| Stroke prevention |
| GYN topics |
| Dermatology rashes |
| HTN |
| HTN management |
| Metabolic syndrome and obesity |
| Drug addiction |
| Obesity |
| HTN treatment |
| Dermatology topics |

| |
|------------------------------|
| Comment |
| COPD management |
| ED |
| ADHD in adults |
| COPD |
| More on prevention |
| ACS |
| Antibiotic use |
| Diabetes and pain management |
| COPD and asthma |
| Dermatitis |
| Treating depression |
| Fibromyalgia |
| Infectious disease topics |
| Opioid management |
| HIV and asthma |
| Diastolic heart failure |
| ADHD |
| Hypertension |
| More oncology topics |
| Substance abuse |
| Thyroid disease |
| Fibromyalgia |
| Obesity |
| RA |
| Lipid lowering agents |
| Depression |
| Pediatric update |
| Dermatology and CKD |
| Dermatology |
| Dyslipidemia and vaccination |

Additional comments:

| Comment |
|--|
| Very impressed by the free charge |
| List brand/generic names |
| Excellent program |
| Thank you-great conference |
| Superb! One of the best CME courses I have been to |
| Great conference |
| Fantastic |
| Better access to parking |
| Excellent and learned many new things |
| Excellent conference |
| Love the activity |
| Excellent conference |
| Thank you |
| I appreciate all of the updates |
| Great experience |
| Very good |
| Easier parking |
| Excellent presentations |
| Excellent program |
| Thanks |
| Thank you |
| Excellent presenters and information |
| Group discussion made it interactive |
| Would you consider applying ANCC or AANP for CME for the program |
| Excellent seminar |
| Excellent conference |
| Make handouts electronically |
| Have on a different weekend than ACP which I attend |
| Great |
| Very well organized and presented |
| Very interesting topics |
| I liked the ARS |
| More time for questions after every lecture |
| Dr. Kuritzky is such an enjoyable speaker |
| Very good meeting |
| Well presented |

Item Statistics:

| | Title | Specialty | Learning Objectives1 | Learning Objectives2 | Learning Objectives3 | Learning Objectives4 | Learning Objectives5 |
|--------------------|-------|-----------|----------------------|----------------------|----------------------|----------------------|----------------------|
| Mean | 1.83 | 2.04 | 1.11 | 1.05 | 1.07 | 1.20 | 1.10 |
| Variance | 1.41 | 5.86 | 0.10 | 0.05 | 0.07 | 0.16 | 0.12 |
| Standard Deviation | 1.19 | 2.42 | 0.32 | 0.23 | 0.26 | 0.40 | 0.35 |
| Standard Error | 0.10 | 0.21 | 0.03 | 0.02 | 0.02 | 0.04 | 0.03 |
| Minimum | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Maximum | 6.00 | 8.00 | 2.00 | 2.00 | 2.00 | 2.00 | 3.00 |
| Median | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Range | 5.00 | 7.00 | 1.00 | 1.00 | 1.00 | 1.00 | 2.00 |

| | Learning Objectives6 | Learning Objectives7 | Overall Activity | Enhancing My Confidence | Improving My Knowledge | Patient Care | Make Changes |
|--------------------|----------------------|----------------------|------------------|-------------------------|------------------------|--------------|--------------|
| Mean | 1.42 | 1.20 | 1.43 | 1.43 | 1.38 | 1.40 | 1.31 |
| Variance | 0.39 | 0.20 | 0.31 | 0.26 | 0.25 | 0.29 | 0.56 |
| Standard Deviation | 0.62 | 0.45 | 0.56 | 0.51 | 0.50 | 0.54 | 0.75 |
| Standard Error | 0.06 | 0.04 | 0.05 | 0.05 | 0.04 | 0.05 | 0.07 |
| Minimum | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Maximum | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 4.00 |
| Median | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Range | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 3.00 |

| | Implement New Strategies | Mark Stolar MD {Diabetes} | Louis Kuritzky MD {A Fib} | Louis Kuritzky MD {CLBP} | Gerald W Dryden MD {IBD} | Marjorie Luckey MD {Osteo} | Franck Rahaghi MD {PAH} |
|--------------------|-----------------------------|------------------------------|------------------------------|-----------------------------|--------------------------------|----------------------------------|-------------------------------|
| Mean | 1.44 | 4.63 | 4.87 | 4.87 | 4.50 | 4.66 | 4.33 |
| Variance | 0.78 | 0.41 | 0.13 | 0.12 | 0.56 | 0.40 | 0.80 |
| Standard Deviation | 0.88 | 0.64 | 0.36 | 0.34 | 0.75 | 0.63 | 0.90 |
| Standard Error | 0.08 | 0.06 | 0.03 | 0.03 | 0.07 | 0.06 | 0.09 |
| Minimum | 1.00 | 2.00 | 3.00 | 4.00 | 1.00 | 2.00 | 1.00 |
| Maximum | 4.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Median | 1.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Range | 3.00 | 3.00 | 2.00 | 1.00 | 4.00 | 3.00 | 4.00 |

| | Franck Rahaghi MD {AAT} | Mark Stolar MD {Diabetes} Bias | Louis Kuritzky MD {A Fib} Bias | Louis Kuritzky MD {CLBP} Bias | Gerald W Dryden MD {IBD} Bias | Marjorie Luckey MD {Osteo} Bias | Franck Rahaghi MD {PAH} Bias |
|--------------------|-------------------------------|--------------------------------------|-----------------------------------|-------------------------------------|-------------------------------------|---------------------------------------|------------------------------------|
| Mean | 4.45 | 4.81 | 4.86 | 4.86 | 4.82 | 4.79 | 4.79 |
| Variance | 0.73 | 0.21 | 0.17 | 0.17 | 0.15 | 0.27 | 0.31 |
| Standard Deviation | 0.85 | 0.45 | 0.42 | 0.41 | 0.38 | 0.52 | 0.56 |
| Standard Error | 0.09 | 0.04 | 0.04 | 0.04 | 0.03 | 0.05 | 0.05 |
| Minimum | 1.00 | 2.00 | 2.00 | 2.00 | 4.00 | 2.00 | 1.00 |
| Maximum | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Median | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Range | 4.00 | 3.00 | 3.00 | 3.00 | 1.00 | 3.00 | 4.00 |

| | Franck Rahaghi MD {AAT} Bias | Reasons for Participating | Future CME Activities |
|--------------------|------------------------------|---------------------------|-----------------------|
| Mean | 4.81 | - | 1.57 |
| Variance | 0.27 | - | 0.42 |
| Standard Deviation | 0.52 | - | 0.65 |
| Standard Error | 0.05 | - | 0.06 |
| Minimum | 1.00 | - | 1.00 |
| Maximum | 5.00 | - | 4.00 |
| Median | 5.00 | - | 1.00 |
| Range | 4.00 | - | 3.00 |